MarketCap
Facebook
X
Telegram
Vivos Therapeutics Income Statement 2025-2011 | VVOS
Brief overview of income trends at Vivos Therapeutics
The comparison covers a five-year financial horizon. The revenue attributed to Vivos Therapeutics moved from 13.1 million dollars to 17.4 million dollars between the two endpoints. The five-year change reached +33.5%, while CAGR stood at 5.9%. Revenue advanced gradually over the five-year period.
At the gross-profit level, the result moved from $10.4 million to $10.5 million, a change of +1.2%. Costs absorbed a larger share of revenue over the period. The gross margin was 79.7% at the start and 60.4% at the end. The contraction points to pressure from direct costs or weaker pricing power.
The five-year EBITDA result moved by −132.6%: from −$8 million to −$18.6 million. Operating performance weakened relative to revenue. EBITDA margin moved from −61.2% to −106.5%. A lower EBITDA share weakens the quality of the result.
Across the five years, the net result shifted from −$12.1 million to −$21.2 million. Profitability deteriorated further over the five years.
Overall conclusion
The current trajectory does not yet confirm a sustainable recovery. The financial profile benefits from revenue expansion. The weaker side of the profile includes pressure from direct costs, pressure on operating profitability and declining net profitability. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Vivos Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
15.1 M | 14.3 M | 5.89 M | 322 K | 70.9 B | 116 M | - | - | - | - | - | - | - | - | - |
Shares |
10.3 M | 5.02 M | 1.22 M | 921 K | 21.2 B | 17.7 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
1.47 | 2.85 | 4.83 | 0.35 | 3.34 | 7.51 | - | - | - | - | - | - | - | - | - |
Net Income |
-21.2 M | -11.1 M | -13.6 M | -23.8 M | -20.3 M | -12.1 M | -10.8 M | -8.44 M | - | - | - | - | - | - | - |
Revenue |
17.4 M | 15 M | 13.8 M | 16 M | 16.9 M | 13.1 M | 11.4 M | 3.79 M | - | - | - | - | - | - | - |
Cost of Revenue |
6.9 M | 6.01 M | 5.53 M | 200 K | 400 K | 100 K | 2.74 M | - | - | - | - | - | - | - | - |
Gross Profit |
10.5 M | 9.02 M | 8.27 M | 10 M | 12.6 M | 10.4 M | 8.66 M | 2.71 M | - | - | - | - | - | - | - |
Operating Income |
-19.9 M | -11.2 M | -17.3 M | -25 M | -20.4 M | -12 M | -10.6 M | - | - | - | - | - | - | - | - |
Interest Expense |
1.4 M | -110 K | -212 K | -190 K | 14 K | 96 K | 138 K | - | - | - | - | - | - | - | - |
EBITDA |
-18.6 M | -10.6 M | -16.7 M | -24.4 M | -19.6 M | -7.99 M | -9.83 M | -7.73 M | - | - | - | - | - | - | - |
Operating Expenses |
30.4 M | 20.2 M | 25.6 M | 35 M | 33 M | 19.1 M | 19.2 M | 11 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
27.7 M | 17.9 M | 22.5 M | 29 M | 25.8 M | 16.1 M | 16.2 M | 9.27 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Vivos Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
14.6 M | 11 M | 9.09 M | 8.6 M | 5.89 M | 6.62 M | 3.23 M | 2.31 M | 1.83 M | 1.2 M | 1.2 M | 991 K | 921 K | 849 K | 21.2 M | 21.2 M | 23 M | 20.8 B | 20.7 B | 18.2 M | 18.2 M | 12.5 M | 12.5 M | 12.5 M | 12.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-7.68 M | -5.4 M | -5.01 M | -3.86 M | - | -2.62 M | -1.93 M | -3.76 M | - | -2.09 M | -5.53 M | -1.7 M | - | -5.43 M | -6.99 M | -5.33 M | - | -5.45 M | -4.04 M | -3.4 M | - | -1.81 M | -1.41 M | -2.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
5.14 M | 6.78 M | 3.82 M | 3.02 M | - | 3.86 M | 4.05 M | 3.42 M | - | 3.3 M | 3.4 M | 3.86 M | - | 4.25 M | 4.18 M | 3.46 M | - | 4.55 M | 4.5 M | 7.74 K | - | 21 K | 21.7 K | 20.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
2.08 M | 2.85 M | 1.71 M | 1.51 M | - | 1.53 M | 1.4 M | 1.48 M | - | 1.55 M | 1.3 M | 100 K | - | 100 K | 100 K | 100 K | - | 100 K | 100 K | 100 K | - | 709 K | 545 K | 780 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
3.06 M | 3.94 M | 2.11 M | 1.51 M | - | 2.33 M | 2.65 M | 1.94 M | - | 1.75 M | 2.1 M | 2.34 M | - | 2.5 M | 2.59 M | 2.37 M | - | 3.18 M | 3.62 M | 2.69 M | - | 2.58 M | 2.73 M | 2.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-6.62 M | -4.73 M | -4.86 M | -3.92 M | - | -2.64 M | -1.94 M | -3.78 M | - | -3.64 M | -4.52 M | -5 M | - | -5.41 M | -6.96 M | -6.82 M | - | -5.5 M | -4.06 M | -3.41 M | - | -1.82 M | -1.42 M | -2.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
1.1 M | 500 K | -163 K | -4 K | - | -18 K | -22 K | -1 K | - | -53 K | -225 K | 51 K | - | -36 K | -37 K | - | - | 9.49 K | 251 | 82 | - | 17 K | 18.1 K | 43.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-6.16 M | -4.35 M | -4.56 M | -3.74 M | - | -2.5 M | -1.79 M | -3.64 M | - | -3.49 M | -4.37 M | -4.83 M | - | -5.23 M | -6.8 M | -6.78 M | - | -4.94 M | -3.69 M | -3.23 M | - | -1.64 M | -1.24 M | -2.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
9.67 M | 8.67 M | 6.98 M | 5.43 M | - | 4.98 M | 4.59 M | 5.72 M | - | 5.39 M | 6.62 M | 7.34 M | - | 7.9 M | 9.55 M | 9.19 M | - | 8.69 M | 7.68 M | 6.1 M | - | 4.4 M | 4.14 M | 4.97 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
8.97 M | 7.88 M | 6.41 M | 4.89 M | - | 4.49 M | 4.12 M | 4.92 M | - | 4.6 M | 5.88 M | 6.54 M | - | 6.62 M | 7.69 M | 8.28 M | - | 6.52 M | 6.09 M | 5.06 M | - | 3.79 M | 3.46 M | 4.23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Vivos Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Britain
Israel
Canada
China
